Barclays’s Lucira Health, Inc. Common Stock LHDX Stock Holding History

Barclays’s Portfolio LHDX Stock Details LHDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-2,906	Closed	-$668	–	5344
2023 Q1	$668	Buy	+2,906	New	+$1.03K	﹤0.01%	4939
2022 Q3	–	Sell	-4,016	Closed	-$7K	–	5283
2022 Q2	$7K	Hold	4,016	–	–	﹤0.01%	4737
2022 Q1	$14K	Buy	+4,016	New	+$19.7K	﹤0.01%	4543

Other funds holding LHDX

Resolute Advisors San Francisco, California $417M AUM 60.99% 1-Year Est. Return

Barclays's LHDX Position: Q2 2023 in Review

Barclays sold out of Lucira Health, Inc. Common Stock (LHDX) in Q2 2023, closing a stake of 2,906 shares — an estimated $668 sold.

Barclays first reported a position in LHDX in Q1 2022 and held it in 3 quarters. The position peaked at $14K in Q1 2022. 1 fund tracked by Wall St. Rank holds LHDX as of Q2 2023.

Barclays reported no remaining Lucira Health, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Barclays sold 2,906 Lucira Health, Inc. Common Stock shares in Q2 2023, an estimated $668.
Barclays first reported a position in Lucira Health, Inc. Common Stock in Q1 2022 and held it in 3 quarters.
Barclays's Lucira Health, Inc. Common Stock position peaked at $14K in Q1 2022.
1 fund tracked by Wall St. Rank held Lucira Health, Inc. Common Stock as of Q2 2023.

Based on Barclays's 13F filing for Q2 2023, filed 3 Aug 2023.